Literature DB >> 11506495

Prognostic utility of human complement factor H related protein test (the BTA stat Test).

M P Raitanen1, E Kaasinen, E Rintala, E Hansson, P Nieminen, R Aine, T L Tammela.   

Abstract

The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan-Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506495      PMCID: PMC2364089          DOI: 10.1054/bjoc.2001.1938

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Improved detection of recurrent bladder cancer using the Bard BTA stat Test.

Authors:  M F Sarosdy; M A Hudson; W J Ellis; M S Soloway; R deVere White; J Sheinfeld; M V Jarowenko; P F Schellhammer; E W Schervish; J V Patel; G W Chodak; D L Lamm; R D Johnson; M Henderson; G Adams; B A Blumenstein; K R Thoelke; R D Pfalzgraf; H A Murchison; S L Brunelle
Journal:  Urology       Date:  1997-09       Impact factor: 2.649

2.  Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer.

Authors:  M P Raitanen; T Marttila; E Kaasinen; E Rintala; R Aine; T L Tammela
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

3.  Impact of tumour grade, stage, number and size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder.

Authors:  M P Raitanen; T L Tammela
Journal:  Ann Chir Gynaecol       Date:  1995

4.  Complement factor H or a related protein is a marker for transitional cell cancer of the bladder.

Authors:  R Kinders; T Jones; R Root; C Bruce; H Murchison; M Corey; L Williams; D Enfield; G M Hass
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

5.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

6.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

7.  Ta and T1 bladder cancer: location, recurrence and progression.

Authors:  N M Heney; B N Nocks; J J Daly; G R Prout; J B Newall; P P Griffin; T L Perrone; W A Szyfelbein
Journal:  Br J Urol       Date:  1982-04

8.  Factors affecting recurrence and progression in superficial bladder tumours.

Authors:  K H Kurth; L Denis; C Bouffioux; R Sylvester; F M Debruyne; M Pavone-Macaluso; W Oosterlinck
Journal:  Eur J Cancer       Date:  1995-10       Impact factor: 9.162

9.  Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection.

Authors:  J M Fitzpatrick; A B West; M R Butler; V Lane; J D O'Flynn
Journal:  J Urol       Date:  1986-05       Impact factor: 7.450

10.  Noninvasive detection of bladder cancer with the BTA stat test.

Authors:  D Pode; A Shapiro; M Wald; O Nativ; M Laufer; I Kaver
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

View more
  4 in total

1.  The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.

Authors:  Mika-P Raitanen
Journal:  World J Urol       Date:  2008-01-08       Impact factor: 4.226

2.  Characterization of the Peri-Membrane Fluorescence Phenomenon Allowing the Detection of Urothelial Tumor Cells in Urine.

Authors:  Charly Gutierrez; Xavier Pinson; Kathleen Jarnouen; Marine Charpentier; Raphael Pineau; Laëtitia Lallement; Rémy Pedeux
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

3.  Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data.

Authors:  Lazaro Hiram Betancourt; Krzysztof Pawłowski; Jonatan Eriksson; A Marcell Szasz; Shamik Mitra; Indira Pla; Charlotte Welinder; Henrik Ekedahl; Per Broberg; Roger Appelqvist; Maria Yakovleva; Yutaka Sugihara; Kenichi Miharada; Christian Ingvar; Lotta Lundgren; Bo Baldetorp; Håkan Olsson; Melinda Rezeli; Elisabet Wieslander; Peter Horvatovich; Johan Malm; Göran Jönsson; György Marko-Varga
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

4.  A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.

Authors:  Jamie J D'Costa; James C Goldsmith; Jayne S Wilson; Richard T Bryan; Douglas G Ward
Journal:  Bladder Cancer       Date:  2016-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.